IP Library Granted Patent US 9,688,960
Granted Patent B2
US 9,688,960 · App. 14/776,132 · Granted Jun 27, 2017

Methods of preserving and protecting pancreatic beta cells and treating or preventing diabetes by inhibiting NOX-1

Inventor: David Taylor-Fishwick (Norfolk, VA)
Assignee: Eastern Virginia Medical School
C12N5/0676A01N1/0226A61K31/437A61K31/444A61K31/5415A61K31/713A61K45/06C07D279/20C07D471/04C12N15/1137C12N2310/14C12N2320/30C12N2501/999
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,688,960
App. No.
14/776,132
Granted
Jun 27, 2017
Kind
B2
Abstract

Methods to preserve and/or protect beta cell function by contacting a population or preparation of pancreatic cells, beta cells and/or islets with an inhibitor of NADPH oxidase-1 (NOX-1). Methods of treating a subject for diabetes by administering a therapeutically effective amount of a NOX-1 inhibitor to the subject.

Claims (12)

1. A method to preserve and/or protect beta cell function comprising contacting a population or preparation of pancreatic cells, beta cells and/or islets with an inhibitor of NADPH oxidase-1 (NOX-1), wherein the NOX-1 inhibitor is a phenothiazine.

2. The method of claim 1 wherein the NOX-1 inhibitor is 2-acetylphenothiazine.

3. The method of claim 1 wherein the pancreatic cells, beta cells and/or islets have been exposed to stressful stimuli.

4. The method of claim 3 wherein the stressful stimuli is selected from the group consisting of inflammation, inflammatory cytokines, high glucose, elevated free fatty acids and combinations thereof.

5. The method of claim 1 wherein the contacting step is in vitro.

6. The method of claim 1 wherein the contacting step is in vivo.

7. The method of claim 1 wherein the contacting step is ex vivo.

8. The method of claim 1 wherein the method further comprises coadministrating with another pharmaceutical agent.

9. The method of claim 1 wherein a preparation of pancreatic cells is contacted.

10. The method of claim 1 wherein a preparation of beta cells is contacted.

11. The method of claim 1 wherein a preparation of islets is contacted.

12. The method of claim 1 wherein the NOX-1 inhibitor is NCTT-1.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 12, 2016
From: TAYLOR-FISHWICK, DAVID
To: EASTERN VIRGINIA MEDICAL SCHOOL
Reel/Frame 037722/0625 →
Continuity (2)
Provisional Application 61783777 · Mar 14, 2013
Related Publication 20160010061A1 · Jan 14, 2016